Sensorium Therapeutics (Sensorium), a biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health,announced the appointment of Jeffrey M. Brown, Ph.D., MBA as Chief Scientific Officer.
In addition to leading a team of world-class scientists, Dr. Brown will oversee the progress of Sensorium’s initial candidate, SENS-01, which is being developed as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression, and its Biodynamic Discovery Platform™ (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances target molecules as novel therapeutics.
Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge
“We are thrilled to strengthen our scientific leadership at this critical phase of development for the company,” said Dick Simon, Chief Executive Officer of Sensorium. “Jeffrey’s impressive background leading preclinical programs and building drug discovery platforms across large pharmaceutical and biotechnology companies will be instrumental as we advance SENS-01 and further leverage the BDP to identify novel drug leads with the potential to address the growing mental health crisis.”
Dr. Brown joins Sensorium from Deep Genomics, where he served as Vice President and Head of Preclinical Research, advancing the company’s discovery pipeline for antisense oligonucleotide therapeutics. Prior to Deep Genomics, he held leadership positions at Voyager Therapeutics, Wave Life Sciences, and Alexion Pharmaceuticals. He previously spent over two decades at Amgen, Pfizer, and Bristol-Myers Squibb. Over the course of his career, he has led more than 20 preclinical programs and successfully advanced several into clinical development. He holds a PhD in Pharmacology/Toxicology from the University of Utah and an MBA from Suffolk University.
Recommended AI News: Fastly Acquires Fanout to Unlock Real-Time App Development at the Edge
“As a devoted drug hunter, I was impressed by Sensorium’s unique approach of applying lessons from nature and what has worked in humans for centuries to create scalable small molecules with the power to transform the current treatment paradigm,” said Dr. Brown. “This passionate and purposeful team has what it takes to go the distance—leveraging cutting-edge science and probing the vast unexplored chemical space of psychoactive plants and fungi toward improving mental health.”
Recommended AI News: CommScope Propels Data Centers into the Future
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.